Category: Immunotherapy

Roche builds case for T-cell bispecific-anti-PD-L1 combo

Roche has published early clinical data on its bispecific antibody in heavily pretreated patients with metastatic colorectal cancer. The readout hints that the T cell-activating antibody may improve outcomes in this hard-to-treat population when given as a monotherapy and in combination with anti-PD-L1 drug Tecentriq. http://www.fiercebiotech.com/biotech/roche-builds-case-for-t-cell-bispecific-anti-pd-l1-combo

Merck’s Keytruda in combination with chemotherapy gets FDA nod to treat NSCLC

Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) and carboplatin (pem/carbo) has been approved by the US Food and Drug Administration (FDA) for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. http://www.pharmaceutical-business-review.com/news/mercks-keytruda-regimen-gets-fda-approval-for-metastatic-nsclc-treatment-110517-5811043

Immunotherapy Companies Leading the Charge for Treating Cancer

NEW YORK, February 21, 2017 /PRNewswire/ — Immuno-oncology is one of the fastest growing and promising areas of cancer research. It is the genesis behind the rapidly expanding field of precision-focused cancer drug development. Immuno-oncology therapeutics is transforming the way… http://www.prnewswire.com/news-releases/immunotherapy-companies-leading-the-charge-for-treating-cancer-614345683.html